Top 100 Cited Papers on Premenstrual Syndrome/Premenstrual Dysphoric Disorder: A Bibliometric Study.
PMDD
bibliometric analysis
citations
premenstrual syndrome
trends
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
05
2022
accepted:
14
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Premenstrual syndrome/premenstrual dysphoric disorder is a serious condition affecting women worldwide, causing clinically significant distress or interference. Therefore, solving these diseases has become the utmost concern worldwide, culminating in numerous studies. In this study, we performed bibliometric analysis on the 100 most cited papers with the aim of identifying research hot spots and trends in this field. We screened the Science Citation Index Expanded (SCIE) of Web of Science (WOS) to identify the top 100 cited studies on PMS/PMDD. Next, we analyzed relevant literature from various journals, countries/regions, institutions, authors, and keywords. Finally, we used VOSviewer and Citespace software to generate knowledge maps and identify hot spots and trends. The top 100 highly cited studies were published in 55 journals, between 1999 and 2017, across 24 countries/regions around the world. Most articles were published in Obstetrics and Gynecology, whereas Psych neuroendocrinology had the largest average number of citations per paper. The United States had the highest number of publications, followed by England, Canada, and Sweden. The top three institutions that published the highly cited literature were the University of Pennsylvania, Yale University, and National Institute of Mental Health (NIMH). Obstetrics, Gynecology, Psychiatry, and Reproductive Biology were the main research directions, whereas the top 10 Co-occurrence of Keywords included double-blind, fluoxetine, efficacy, prevalence, epidemiology, phase sertraline treatment, depression, progesterone, placebo, and placebo-controlled trial. Results from cluster analysis indicated that more comprehensive epidemiology and steroid pathogenesis have gradually become the hot spots and trends. These findings demonstrated that bibliometric analysis can intuitively and rapidly reveal the frontiers and hot spots of research in PMS/PMDD. Notably, epidemiology, steroid pathogenesis, GABAA receptor delta subunits, and double-blind placebo-controlled trials are potential areas of focus for future research.
Sections du résumé
Background
UNASSIGNED
Premenstrual syndrome/premenstrual dysphoric disorder is a serious condition affecting women worldwide, causing clinically significant distress or interference. Therefore, solving these diseases has become the utmost concern worldwide, culminating in numerous studies. In this study, we performed bibliometric analysis on the 100 most cited papers with the aim of identifying research hot spots and trends in this field.
Methods
UNASSIGNED
We screened the Science Citation Index Expanded (SCIE) of Web of Science (WOS) to identify the top 100 cited studies on PMS/PMDD. Next, we analyzed relevant literature from various journals, countries/regions, institutions, authors, and keywords. Finally, we used VOSviewer and Citespace software to generate knowledge maps and identify hot spots and trends.
Results
UNASSIGNED
The top 100 highly cited studies were published in 55 journals, between 1999 and 2017, across 24 countries/regions around the world. Most articles were published in Obstetrics and Gynecology, whereas Psych neuroendocrinology had the largest average number of citations per paper. The United States had the highest number of publications, followed by England, Canada, and Sweden. The top three institutions that published the highly cited literature were the University of Pennsylvania, Yale University, and National Institute of Mental Health (NIMH). Obstetrics, Gynecology, Psychiatry, and Reproductive Biology were the main research directions, whereas the top 10 Co-occurrence of Keywords included double-blind, fluoxetine, efficacy, prevalence, epidemiology, phase sertraline treatment, depression, progesterone, placebo, and placebo-controlled trial. Results from cluster analysis indicated that more comprehensive epidemiology and steroid pathogenesis have gradually become the hot spots and trends.
Conclusion
UNASSIGNED
These findings demonstrated that bibliometric analysis can intuitively and rapidly reveal the frontiers and hot spots of research in PMS/PMDD. Notably, epidemiology, steroid pathogenesis, GABAA receptor delta subunits, and double-blind placebo-controlled trials are potential areas of focus for future research.
Identifiants
pubmed: 35911247
doi: 10.3389/fpsyt.2022.936009
pmc: PMC9329608
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
936009Informations de copyright
Copyright © 2022 Gao, Zhang, Wang, Mou, Zhu, Wang and Gao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2021 Dec 03;11:795568
pubmed: 34926312
Neuropsychiatr Dis Treat. 2020 Feb 10;16:415-426
pubmed: 32103961
Perspect Psychiatr Care. 2018 Jul;54(3):348-353
pubmed: 29215138
J Womens Health (Larchmt). 2008 Jan-Feb;17(1):113-21
pubmed: 18240988
Acta Obstet Gynecol Scand. 2000 May;79(5):405-13
pubmed: 10830769
BMC Womens Health. 2022 Feb 11;22(1):35
pubmed: 35148753
Psychopharmacology (Berl). 2016 Jun;233(11):2109-2117
pubmed: 26960697
Rev Bras Ginecol Obstet. 2022 Feb;44(2):133-141
pubmed: 35213911
Arch Womens Ment Health. 2010 Dec;13(6):485-94
pubmed: 20449618
Am J Psychiatry. 2017 Oct 1;174(10):980-989
pubmed: 28427285
J Affect Disord. 2002 Jul;70(2):125-32
pubmed: 12117624
Psychol Med. 2009 Jan;39(1):129-36
pubmed: 18366818
Gynecol Endocrinol. 2007 Mar;23(3):123-30
pubmed: 17454164
J Womens Health (Larchmt). 2009 Jan-Feb;18(1):31-9
pubmed: 19105683
Molecules. 2021 Dec 08;26(24):
pubmed: 34946512
Afr J Prim Health Care Fam Med. 2021 Aug 30;13(1):e1-e9
pubmed: 34476974
Depress Anxiety. 2018 Dec;35(12):1168-1177
pubmed: 30184299
Arch Gen Psychiatry. 2002 Sep;59(9):851-8
pubmed: 12215085
J Psychosom Obstet Gynaecol. 2000 Jun;21(2):69-80
pubmed: 10994179
Acta Psychiatr Scand. 2017 Nov;136(5):473-482
pubmed: 28846801
Arch Womens Ment Health. 2017 Dec;20(6):713-719
pubmed: 29063202
Am Fam Physician. 2016 Aug 1;94(3):236-40
pubmed: 27479626
BMC Med. 2022 Feb 21;20(1):60
pubmed: 35184745
Obstet Gynecol. 2005 Sep;106(3):492-501
pubmed: 16135578
Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:1-23
pubmed: 12892987
Psychol Med. 2002 Jan;32(1):119-32
pubmed: 11883723
Neurobiol Stress. 2020 Feb 04;12:100213
pubmed: 32435664
Front Public Health. 2021 Apr 21;9:596128
pubmed: 33968873
BMC Psychiatry. 2021 Nov 9;21(1):548
pubmed: 34753455
Lancet. 2000 Sep 30;356(9236):1131-6
pubmed: 11030291
CNS Drugs. 2006;20(7):523-47
pubmed: 16800714
Am J Psychiatry. 2012 May;169(5):465-75
pubmed: 22764360
J Neuroendocrinol. 2018 Feb;30(2):
pubmed: 29072794
JAMA Netw Open. 2022 Mar 1;5(3):e221256
pubmed: 35258576
Arch Womens Ment Health. 2006 Jul;9(4):209-12
pubmed: 16761114
Periodontol 2000. 2021 Feb;85(1):237-240
pubmed: 33226679
Front Psychiatry. 2021 Aug 25;12:719241
pubmed: 34512419
BMC Womens Health. 2014 Mar 29;14:52
pubmed: 24678964
Pharmacol Ther. 2007 Oct;116(1):58-76
pubmed: 17512983
Front Psychiatry. 2020 Jun 30;11:572
pubmed: 32695026
Arch Womens Ment Health. 2022 Feb;25(1):61-70
pubmed: 34436653
Am J Obstet Gynecol. 2018 Jan;218(1):68-74
pubmed: 28571724
J Psychosom Obstet Gynaecol. 2006 Dec;27(4):201-10
pubmed: 17225621
J Affect Disord. 2021 Dec 1;295:339-346
pubmed: 34488087
Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):18-23
pubmed: 9914571
Am J Obstet Gynecol. 1950 Aug;60(2):343-52
pubmed: 15432533
Arch Womens Ment Health. 2022 Apr;25(2):345-353
pubmed: 35226173
Gene. 2022 Jan 30;809:146021
pubmed: 34673206
Braz J Psychiatry. 2012 Dec;34(4):467-79
pubmed: 23429819